The present disclosure encompasses compositions prepared from kiwifruit. In particular, the invention encompasses compositions prepared from gold varieties of Actinidia chinensis. Also encompassed are methods of preparing these compositions. Further encompassed are methods of using these compositions, in particular, for treating or preventing disorders of the gastrointestinal system, including amongst others: inflammation, constipation, bowel irregularity, microbiota imbalances, irritable bowel syndrome, and inflammatory bowel disease.

The present invention relates to pharmaceutical compositions having improved stability.

The present invention pertains to inter alia methods for purifying extracellular vesicles including exposing a sample comprising at least one extracellular vesicle to ultrafiltration; and exposing the sample following the ultrafiltration in step (i) to size exclusion liquid chromatography.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Provided is a prebiotic composition, including a kiwifruit fermented product, inulin, and fructooligosaccharide, where the weight ratio of the kiwifruit fermented product, the inulin, and the fructooligosaccharide is 3-4:2.5-4:2.5-4. Based on this, the prebiotic composition prepared from the kiwifruit fermented product and sugars can be used for improving an intestinal tract of a subject.

Provided is a prebiotic composition, including a kiwifruit fermented product, inulin, and fructooligosaccharide, where the weight ratio of the kiwifruit fermented product, the inulin, and the fructooligosaccharide is 3-4:2.5-4:2.5-4. Based on this, the prebiotic composition prepared from the kiwifruit fermented product and sugars can be used for improving an intestinal tract of a subject.

A method of increasing apparent total tract digestibility and retention of calcium and phosphorus in a pig is provided. The method includes administering to the pig an effective amount of a vitamin D composition comprising at least one vitamin D compound. Related compositions are also provided.

A method of increasing apparent total tract digestibility and retention of calcium and phosphorus in a pig is provided. The method includes administering to the pig an effective amount of a vitamin D composition comprising at least one vitamin D compound. Related compositions are also provided.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.